OB/GYN & Women’s Health – Page 12

Nationwide Prevention Programme in Australia Associated with Lower Preterm and Early‑Term Singleton Births: National and Hospital‑Level Results

By MedXY 11/07/2025

A multifaceted national preterm birth prevention programme in Australia was associated with a modest national decrease in late preterm births and, after a hospital collaborative, a substantial reduction in early‑term births in participating centres, without increasing preterm rates.

news OB/GYN & Women's Health

Blocking the Prolactin Receptor for Endometriosis Pain: HMI-115 Phase II Shows Dose-Dependent Analgesia Without Hypoestrogenic Effects

By MedXY 11/07/2025

A multicenter phase II trial of HMI-115, a human monoclonal antibody against the prolactin receptor, showed dose-dependent reductions in endometriosis-associated pain and preserved ovarian function, supporting larger Phase III evaluation.

news OB/GYN & Women's Health Public Health

Long-Term Effectiveness of HPV Screen-and-Treat Strategy Versus Cytology in Cervical Cancer Screening: Insights from El Salvador’s CAPE Program

By MedXY 10/31/2025

A 5-year follow-up study in El Salvador demonstrates that primary HPV screen-and-treat significantly reduces CIN2+ detection and HPV positivity compared to cytology, supporting extended screening intervals in low-resource settings.

Infectious Diseases news OB/GYN & Women's Health

Prophylactic Antibiotics in Episiotomy and Second Degree Tears: Insights from the REPAIR Trial

By MedXY 10/31/2025

The REPAIR study demonstrates that prophylactic antibiotics reduce clinically relevant wound complications after episiotomy or second degree tears, highlighting a potential role for antibiotics in postpartum care.

news OB/GYN & Women's Health Public Health

Review for Cervical Cancer Screening

By MedXY 10/31/2025

A comprehensive 2025 systematic review informing the Canadian Task Force finds cytology remains effective into the 60s, HPV-based strategies detect more precursors but increase colposcopy and false positives, and self-sampling improves uptake in underscreened people.

news OB/GYN & Women's Health Oncology

Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer

By MedXY 10/31/2025

Trastuzumab deruxtecan combined with pertuzumab significantly improves progression-free survival over standard therapy in first-line HER2-positive metastatic breast cancer, offering enhanced response duration with manageable safety.

news OB/GYN & Women's Health Psychiatry

Behavioral Activation Reduces Perinatal Suicide Ideation: Insights from the SUMMIT Trial

By MedXY 10/27/2025

A secondary analysis of the SUMMIT trial shows that brief behavioral activation therapy significantly reduces suicide ideation in perinatal women, regardless of clinician type or treatment modality, highlighting a scalable approach for suicide prevention in this vulnerable population.

news OB/GYN & Women's Health Public Health

Early Diagnosis of Postpartum Haemorrhage: Insights from the E-MOTIVE Trial in Africa

By MedXY 10/25/2025

This study nested within the E-MOTIVE trial reveals that using a lower blood loss threshold combined with clinical signs leads to earlier postpartum haemorrhage diagnosis and intervention, potentially reducing adverse outcomes in diverse African settings.

OB/GYN & Women's Health Oncology

Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan

By MedXY 10/24/2025

This review discusses a phase 3 trial demonstrating that sacituzumab govitecan improves progression-free survival in untreated, advanced triple-negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.

OB/GYN & Women's Health Oncology

Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer

By MedXY 10/24/2025

Roche announces positive phase 3 results of giredestrant plus everolimus, significantly reducing disease progression risk in ER+ HER2- advanced breast cancer patients post CDK4/6 inhibitor exposure, with favorable safety and promising survival trends.

OB/GYN & Women's Health

FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes

By MedXY 10/24/2025

Bayer's Lynkuet (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, has received FDA approval for treatment of moderate to severe menopausal vasomotor symptoms, demonstrating sustained efficacy and favorable safety in phase 3 trials.

Diabetes & Endocrinology OB/GYN & Women's Health

Closed-Loop Insulin Delivery in Type 1 Diabetes During Pregnancy: Insights from the CIRCUIT Randomized Clinical Trial and Contemporary Evidence

By MedXY 10/24/2025

The CIRCUIT trial demonstrates that closed-loop insulin delivery significantly improves glycemic control during pregnancy in type 1 diabetes, increasing time in pregnancy-specific glucose range and reducing hypoglycemia risks relative to standard care.

OB/GYN & Women's Health Plastic Surgery Urology

Developing a Patient-Centered Counseling Tool for Resuming Sexual Activity After Pelvic Reconstructive Surgery: A Qualitative and Cognitive Interview Approach

By MedXY 10/24/2025

A novel, evidence-based counseling tool was developed to guide patients in safely resuming sexual activity after pelvic reconstructive surgery. The tool integrates patient perspectives and expert input, addressing safety, discomfort, and recovery expectations.

General Surgery OB/GYN & Women's Health Plastic Surgery Public Health

Advancing Sustainability in Gynecologic Surgery: 12 Practical Steps to Reduce Environmental Impact

By MedXY 10/24/2025

This article reviews 12 evidence-backed strategies to enhance sustainability in gynecologic surgery by minimizing single-use disposables and reducing carbon emissions in the operating room.

Diabetes & Endocrinology OB/GYN & Women's Health Specialties

Navigating the Frontiers of Premature Ovarian Insufficiency Research: Insights from the Top 100 Influential Articles

By MedXY 10/22/2025

A comprehensive bibliometric analysis of the 100 most-cited articles in premature ovarian insufficiency reveals key research trends, leading contributors, and emerging scientific directions in genetics, cardiovascular disease, and immunology.

OB/GYN & Women's Health Oncology Radiology Specialties

Personalizing Radiotherapy in Ductal Carcinoma In Situ Using a 12-Gene Expression Assay: Insights from a Prospective Clinical Trial

By MedXY 10/21/2025

This clinical trial prospectively evaluates how a 12-gene expression assay (DCIS score) guides postoperative radiotherapy decisions after breast-conserving surgery in ductal carcinoma in situ, showing tailored radiotherapy use may reduce ipsilateral breast events.

OB/GYN & Women's Health Public Health

From Adolescence to Adulthood: The Lasting Impact of Dysmenorrhoea on Chronic Pain Risk

By MedXY 10/19/2025

A UK cohort study reveals that adolescent dysmenorrhoea increases the risk of chronic pain in adulthood, highlighting the need for early identification and management.

Hematology-Oncology OB/GYN & Women's Health Specialties

Ki-67 Dynamics During Neoadjuvant Chemotherapy: A Key to Better Breast Cancer Prognosis

By MedXY 10/18/2025

This study highlights the prognostic significance of tumor Ki-67 changes during neoadjuvant treatment, offering potential for improved risk stratification and personalized therapy in breast cancer patients.

OB/GYN & Women's Health Psychiatry Specialties

Evaluating the Effectiveness of Circle of Security-Parenting for Perinatal Mental Health: Insights from a Large-Scale RCT

By MedXY 10/18/2025

This study finds no significant benefit of the Circle of Security-Parenting intervention added to usual care for improving mental health and bonding among new parents in NHS settings.

OB/GYN & Women's Health Oncology Specialties

Assessing the Nationwide Prevalence and Outcomes of Breast Cancer Patients Eligible for Adjuvant CDK4/6 Inhibitors

By MedXY 10/18/2025

This study offers insights into the prevalence, characteristics, and long-term survival of breast cancer patients eligible for adjuvant CDK4/6 inhibitors, highlighting real-world outcomes compared to clinical trial populations.